Premium
NR5A2 discovering compounds that block tumor growth in PDAC
Author(s) -
Fletterick Robert
Publication year - 2017
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24639
Subject(s) - transcription factor , liver receptor homolog 1 , cancer research , enhancer , reprogramming , nuclear receptor , medicine , small heterodimer partner , oncogene , farnesoid x receptor , microbiology and biotechnology , cancer , biology , cell , cell cycle , gene , genetics
Pancreatic cancers depend on driver molecules, oncogene proteins such as RAS. NR5A2 protein is a transcription factor and either activates or inhibits transcription through actions at hundreds of enhancers. It has unusual properties with effects appearing in multiple signaling networks. NR5A2 is a pluripotency reprogramming factor in the class nuclear receptor. Its controlling hormone is PIP3. Experiments suggest NR5A2 activation drives PDAC and inhibitors blunt cancer cell proliferation.